ACARBOSE

Post-LOE

acarbose

ANDAORALTABLET
Approved
Jul 2011
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

alpha Glucosidase Inhibitors

Pharmacologic Class:

alpha-Glucosidase Inhibitor

Clinical Trials (5)

NCT04665570N/ACompleted

A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D)

Started Dec 2020
2,000 enrolled
Type 2 Diabetes Mellitus
NCT04180813N/ATerminated

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Started Mar 2020
85 enrolled
Diabetes Mellitus, Type 2
NCT04065581Phase 1Completed

Bioequivalence Study for Acarbose/Metformin FDC

Started Oct 2019
24 enrolled
Diabetes Mellitus, Type 2
NCT03794336Phase 4Completed

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

Started Jun 2019
1,293 enrolled
Type 2 Diabetes Mellitus
NCT03805191N/AUnknown

A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients

Started Jan 2019
900 enrolled
Type 2 Diabetes MellitusPoor Glycemic Control